Previous close | 2.2300 |
Open | 2.2300 |
Bid | 1.9000 |
Ask | 2.9000 |
Strike | 0.50 |
Expiry date | 2024-09-20 |
Day's range | 2.2300 - 2.2300 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement in patients.
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
A week ago, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) came out with a strong set of quarterly numbers that could...